Corvus Pharmaceuticals (CRVS) Operating Income (2015 - 2026)

Corvus Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$14.9 million for Q1 2026.

• On a quarterly basis, Operating Income fell 49.94% year-over-year to -$14.9 million in Q1 2026; TTM through Mar 2026 was -$45.6 million, a 55.39% decrease from a year earlier, with the FY2023 full-year figure at -$23.4 million, up 28.12% from the prior year.
• Operating Income retreated to -$14.9 million in Q1 2026 per CRVS's latest filing, from -$10.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$5.6 million in Q3 2023 and bottomed at -$14.9 million in Q1 2026.
• The 5-year median for Operating Income is -$7.0 million (2022), against an average of -$8.1 million.
• Across the five-year window, Operating Income surged 55.42% in 2023 and sank 72.87% in 2025, its largest moves.
• Year by year, Operating Income stood at -$5.7 million in 2022, then grew by 0.26% to -$5.7 million in 2023, then slipped by 28.38% to -$7.3 million in 2024, then tumbled by 45.72% to -$10.6 million in 2025, then sank by 40.72% to -$14.9 million in 2026.
• Per Business Quant, the three latest CRVS Operating Income figures stand at -$14.9 million (Q1 2026), -$10.6 million (Q3 2025), and -$10.3 million (Q2 2025).